hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06312748 id: 138675 briefTitle: Novel Approaches for Improving Vascular Function in Veterans With HFpEF overallStatus: RECRUITING date: 2021-05-19 date: 2028-09-30 date: 2030-09-30 date: 2024-03-15 date: 2024-03-21 name: D. Walter Wray class: OTHER name: US Department of Veterans Affairs briefSummary: This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF). conditions: HFpEF - Heart Failure With Preserved Ejection Fraction conditions: Inflammation studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: A block randomization method will be used to randomize participants into equal groups and will be handled by investigational pharmacist. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 90 type: ESTIMATED name: L-Citrulline name: Placebo for L-Citrulline name: BH4 name: Placebo for BH4 name: Atorvastatin name: Placebo for Atorvastatin measure: Flow-mediated dilation (FMD) measure: Passive Limb Movement (PLM) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: George E. Whalen VA Medical Center status: RECRUITING city: Salt Lake City state: Utah zip: 84128 country: United States name: Walter Wray role: CONTACT phone: 858-205-3078 email: walter.wray@hsc.utah.edu lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06312735 id: 230405 briefTitle: VR for Patients With Chronic Pain (Wait & Work) overallStatus: RECRUITING date: 2023-10-01 date: 2024-03-31 date: 2024-09-30 date: 2024-03-15 date: 2024-03-18 name: University of Twente class: OTHER briefSummary: This cluster-RCT evaluates the effect of therapeutic virtual reality (VR) on patients with chronic musculoskeletal pain (CMP) who are on a waiting list to receive pain treatment. The used VR application, Reducept, offers pain education and pain management techniques. This home-based, stand-alone, immersive VR intervention was used daily for four weeks in the intervention group. The control group received standard care (no treatment). Primary outcome measure for this study was health-related quality of life, secondary outcome measures included various pain-related variables (e.g. pain self-efficacy and acceptance. Outcome variables will be measured after four weeks and follow-up after six months. conditions: Chronic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: VR (Reducept) measure: Change in quality of life measured using the short-form 12 (SF-12) measure: Change in pain intensity measured using the numeric pain rating scale (NPRS) measure: Change in pain catastrophizing measured using the pain catastrophizing scale (PCS) measure: Change in pain self-efficacy measured using the pain self-efficacy questionnaire (PSEQ) measure: Change in pain acceptance measured using the chronic pain acceptance questionnaire (CPAQ-8) measure: Change in feelings of anxiety and depression measured using the hospital anxiety and depression scale (HADS) measure: Change in quality of care measured using the client satisfaction questionnaire (CSQ-8) measure: Change in medication use measured using an open-ended question sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Revalidatie Friesland status: RECRUITING city: Emmeloord state: Friesland zip: 8303BX country: Netherlands name: Heleen Reinders-Messelink, PhD role: CONTACT lat: 52.71083 lon: 5.74861 facility: Deventer Ziekenhuis status: RECRUITING city: Deventer state: Overijssel zip: 7416SE country: Netherlands name: Leonie Oolbekkink, MSc role: CONTACT lat: 52.255 lon: 6.16389 facility: Roessingh rehabilitation center status: RECRUITING city: Enschede state: Overijssel zip: 7522AH country: Netherlands name: Marjolein Stegeman, MSc role: CONTACT lat: 52.21833 lon: 6.89583 facility: Nocepta status: RECRUITING city: Hengelo state: Overijssel zip: 7555DL country: Netherlands name: Nelson Oliveira, MSc role: CONTACT lat: 52.26583 lon: 6.79306 hasResults: False
nctId: NCT06312722 id: PR1309 briefTitle: Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study acronym: PEAK overallStatus: RECRUITING date: 2024-02-07 date: 2031-02-07 date: 2031-02-07 date: 2024-03-15 date: 2024-03-15 name: Urotronic Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System. conditions: Benign Prostatic Hyperplasia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, single-arm, multi-center, post market clinical trial primaryPurpose: TREATMENT masking: NONE count: 92 type: ESTIMATED name: Optilume® BPH Catheter System measure: The primary efficacy endpoint is the average IPSS improvement from baseline to 12 months. measure: Semen Sub-Study Safety Secondary Endpoint sex: MALE minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Urotronic, INC status: RECRUITING city: Plymouth state: Minnesota zip: 55441 country: United States name: Jill Moland role: CONTACT email: jmoland@laborie.com name: Brandon Shuler role: CONTACT email: bshuler@laborie.com lat: 45.01052 lon: -93.45551 hasResults: False
nctId: NCT06312709 id: STUDY00021288 id: K23HL159240 type: NIH link: https://reporter.nih.gov/quickSearch/K23HL159240 briefTitle: teleABLE to Reduce Post-Stroke Sedentary Behavior overallStatus: RECRUITING date: 2024-04-04 date: 2026-01-31 date: 2026-07-31 date: 2024-03-15 date: 2024-04-10 name: University of Minnesota class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The goal of this clinical trial to test whether a remotely delivered behavioral activation-based intervention called "teleABLE" works better than a health education intervention for (1) reducing sitting time and (2) improving health-related quality among adults who were diagnosed with stroke within the past 12 months.
* Complete an interview at Week 24 conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 92 type: ESTIMATED name: teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement) name: Health Education measure: Between-group difference in change scores on health-related quality of life measure: Between-group difference in change in sedentary behavior measure: Between-group difference in change in sedentary behavior measure: Between-group difference in change scores on health-related quality of life measure: Between-group difference in change in step count measure: Between-group difference in change in step count measure: Between-group difference in change in total activity retention measure: Between-group difference in change in total activity retention sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: School of Kinesiology, University of Minnesota status: RECRUITING city: Minneapolis state: Minnesota zip: 55455 country: United States name: Karli Jahnke, MOT, OTR/L role: CONTACT phone: 612-626-4046 email: dwell@umn.edu lat: 44.97997 lon: -93.26384 hasResults: False
nctId: NCT06312696 id: SMT briefTitle: Normalizing Cervical Intersegmental Kinematics With Spinal Manipulative Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-04-01 date: 2027-04-01 date: 2024-03-15 date: 2024-03-15 name: University of Minnesota class: OTHER briefSummary: The broad long-term objective is to develop an objective biomarker for spinal health based on aberrant or abnormal movement patterns during functional activities to better target spinal manipulation therapy (SMT) and other conservative treatments. The central hypotheses are a) that aberrant spinal motions and their location (area and level) are indicative of underlying spinal dysfunction, and b) that quantified 3D cervical spine intersegmental and global motion patterns during functional tasks can be used as a biomarker for subsequent clinical studies aimed at normalizing cervical kinematics.
Specific Aim: Determine the extent to which SMT can modulate, or normalize, intersegmental motion in patients with neck pain. Rationale: SMT is a force-based biomechanical event whose hypothesized mechanism of action relies on moving the segment into the para-physiological zone, resulting in normalization of spinal kinematic function. Hypothesis: Severity of abnormal or aberrant motion, identified in those with NP, will improve following SMT. Approach: Participants with chronic mechanical neck pain will be recruited and randomized into one of three groups: 1) No Treatment, 2) Light Massage (pseudo- sham), and 3) Spinal Manipulative Therapy. Using a repeated measures study design, metrics of quality of spinal motion will be compared before and after the prescribed intervention. conditions: Neck Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants with chronic mechanical neck pain will be recruited and randomized into one of three groups: 1) No Treatment, 2) Light Massage (pseudo- sham), and 3) Spinal Manipulative Therapy. Using a repeated measures study design, metrics of quality of spinal motion will be compared before and after the prescribed intervention. primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: SMT name: Light Massage measure: Intersegmental and Global Range of Motion measure: Neck pain intensity measure: Neck disability measure: physical function measure: depression measure: sleep disturbance measure: Pain interference measure: Fear of pain assessment measure: Overall function assessment sex: ALL minimumAge: 18 Years maximumAge: 39 Years stdAges: ADULT hasResults: False
nctId: NCT06312683 id: 23-2111 briefTitle: Rifaximin for the Secondary Prevention of Recurrent Pouchitis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-03-15 date: 2024-03-18 name: University of North Carolina, Chapel Hill class: OTHER name: Bausch Health Americas, Inc. briefSummary: Although many people will develop recurrent pouchitis (inflammation of the ileal pouch-anal anastomosis or J-pouch after colectomy for ulcerative colitis) after an initial episode of pouchitis, there are currently no effective treatments to prevent recurrent pouchitis. The goal of this study is to evaluate the potential for rifaximin, an antibiotic, to prevent recurrent pouchitis after treatment for an initial episode of pouchitis. In this study, all patients will be given daily rifaximin for one year after being treated for an initial episode of pouchitis. This study will examine whether people are willing to take rifaximin for one year with the goal of preventing recurrent pouchitis. Additionally, this study will examine whether patients experience any unexpected side effects of rifaximin therapy. The information gained through this study will potentially be helpful in improving the ability to prevent recurrent pouchitis in patients who have a colectomy for ulcerative colitis. conditions: Pouchitis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 8 type: ESTIMATED name: Rifaximin 550 MG Oral Tablet [XIFAXAN] measure: Percentage of Participants Who Develop Recurrent Pouchitis sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of North Carolina city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Mikki Sandridge role: CONTACT phone: 919-843-3873 email: mikki_sandridge@med.unc.edu name: Edward Barnes, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06312670 id: CASE2823 briefTitle: Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2026-03-01 date: 2026-03-01 date: 2024-03-15 date: 2024-04-02 name: Pedro Barata, MD, MSc class: OTHER name: ESSA Pharma Inc. briefSummary: The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer. The main goals of this study are to evaluate the antitumor activity of EPI-7386 in combination with enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC), and to evaluate the pharmacokinetics (PK) of EPI-7386 when dosed in combination with enzalutamide. Participants will will take the study drug, EPI-7360, twice a day by mouth and enzalutamide once a day by mouth, alongside clinic visits every two weeks. conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) conditions: Prostate Cancer conditions: Prostate Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Phase 2, single-arm study composed of 2 stages: in the first stage, 13 subjects diagnosed with mHSPC will be enrolled and treated with EPI-7386 in combination with enzalutamide. If there are 8 or less subjects with a biochemical response at 6 months, then the trial will be suspended. Otherwise, 22 additional subjects will be enrolled and treated. primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: EPI-7386 name: Enzalutamide name: Androgen Deprivation Therapy (ADT) measure: Biochemical response rate measure: PSA progesterone-free survival (PFS) measure: Radiographic PFS (rPFS) measure: ORR (confirmed) measure: AUC0-24 measure: Maximum concentration (Cmax) measure: Predose Plasma Concentration measure: Time to reach Cmax (Tmax) measure: Terminal elimination half-life measure: Volume of distribution at steady state after extravascular administration measure: Clearance after extravascular administration measure: Treatment-emergent adverse events measure: Rate of abnormalities in clinical laboratory parameters measure: Rate of abnormalities in vital sign measurements measure: Rate of bnormalities in electrocardiograms (ECGs) measure: Changes in Eastern Cooperative Oncology Group (ECOG) performance status sex: MALE minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44106 country: United States name: Pedro Barata, MD, MSc role: CONTACT phone: 216-262-1214 email: Pedro.Barata@UHhospitals.org lat: 41.4995 lon: -81.69541 facility: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44195 country: United States name: Christopher Wee, MD role: CONTACT phone: 866-223-8100 email: TaussigResearch@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06312657 id: 81971 briefTitle: Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice acronym: BED(In)(44) overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-03-28 date: 2026-03-28 date: 2024-03-15 date: 2024-04-17 name: Joshua A. Lile, Ph.D. class: OTHER briefSummary: The objective of this protocol is to use probabilistic choice tasks, reinforcement learning modeling and fMRI to determine the neurobehavioral mechanisms of decision-making in individuals with opioid use disorder and physical opioid dependence. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 18 type: ESTIMATED name: Drug Cue name: Money name: Withdrawal measure: Task choices sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06312644 id: D9289C00007 briefTitle: Study of Ultomiris® (Ravulizumab) Safety in Pregnancy overallStatus: NOT_YET_RECRUITING date: 2024-03-29 date: 2033-10-21 date: 2033-10-21 date: 2024-03-15 date: 2024-03-15 name: Alexion Pharmaceuticals, Inc. class: INDUSTRY briefSummary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk. conditions: Ultomiris-exposed Pregnant/ Postpartum conditions: Pregnancy conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) conditions: Atypical Hemolytic Uremic Syndrome (aHUS) conditions: Generalized Myasthenia Gravis (gMG) conditions: Neuromyelitis Optica Spectrum Disorder (NMOSD) studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 300 type: ESTIMATED name: Ultomiris measure: Number of Pregnancy Complications measure: Number of Maternal Complications measure: Fetal/Infant Outcomes sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06312631 id: RC31/21/0342 briefTitle: Home Grip Assistance Glove on the Use of the Upper Limb and Compliance Factors in Brain-injured Adults acronym: ECO-HAND-AVC overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2026-12-31 date: 2024-03-15 date: 2024-03-15 name: University Hospital, Toulouse class: OTHER briefSummary: On a functional level, performing the actions of daily life requires coordinated activity of the muscles of the upper limbs. The quality of motor recovery and/or technical assistance aimed at compensating for the movement deficit of the paretic upper limb (MSP) determines the possibilities of using the upper limb (MS) in activities of daily life.
Our study focuses on a new technical aid device, standard orthosis type, expanding the range of gripping gloves: the SaeboGlove in everyday environments. These MS orthoses help improve the use and function of the MSP in post-stroke adults as well as their independence and participation in society. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Putting on the gripping glove name: ULPA questionnaire name: Motor Activity Log (MAL) Questionnaire name: Fugl-Meyer Assessment Upper Extremity (FMA-UE) questionnaire name: Score Action Arm Research Test name: EuroQol five-level (EQ-5D-5L) questionnaire name: Quebec User Evaluation of Satisfaction with Assistive Technology name: Psychosocial Impact of Assistive Devices Scale (PIADS) name: Goal Attainment Scale (GAS) name: installation and collection of accelerometers measure: Evaluation of the effectiveness of the gripping glove measure: Evaluation of the performance of an activity in the real context of the patient measure: Evaluation of factual spontaneous use of the upper limb in daily life measure: Evaluation of the perceived performance of the use of the paretic upper limb measure: Assessment of the quality of voluntary motor skills of the upper limb measure: Assessment of gripping abilities measure: Quality of life assessment measure: Evaluation of satisfaction and tolerance measure: Evaluation of the psycho-social impact sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Claire VILLEPINTE city: Toulouse state: CHU De Toulouse zip: 31059 country: France name: Claire VILLEPINTE role: CONTACT phone: 5 67 77 17 24 phoneExt: +33 email: villepinte.c@chu-toulouse.fr name: Audrey TOMASIK role: CONTACT phone: 561778597 phoneExt: +33 email: tomasik.a@chu-toulouse.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06312618 id: FMASU MD292/2023 briefTitle: Propofol Versus Dexmedetomidine Effect on Prevention Emergence Agitation overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-09-15 date: 2024-10-15 date: 2024-03-15 date: 2024-03-15 name: Ain Shams University class: OTHER briefSummary: The goal of this clinical trial is to compare Propofol versus Dexmedetomidine in children undergoing squint surgery. The main question it aims to answer is:
Emergence agitation (EA) is a period of restlessness, agitation, inconsolable crying, disorientation, delusions, and hallucinations with impaired cognition and memory that commonly occurs in children undergoing ophthalmic surgery especially after Short acting volatile agents such as sevoflurane. conditions: Emergence Agitation studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 30 type: ESTIMATED name: Propofol name: Dexmedetomidine measure: the overall incidence of postoperative Emergence Agitation measure: Vital signs change. measure: Vital signs change. measure: Vital signs change. measure: Proportion of patients with adverse events in the PACU measure: Proportion of patients with Post Operative Nausea and Vomiting (PONV) sex: ALL minimumAge: 3 Years maximumAge: 7 Years stdAges: CHILD hasResults: False
nctId: NCT06312605 id: 230620 briefTitle: The Adjunctive Role of Vitamin C on Pigment Recurrence (Randomized Clinical and Histological Trial) overallStatus: RECRUITING date: 2023-08-01 date: 2024-08 date: 2024-08 date: 2024-03-15 date: 2024-03-15 name: Ain Shams University class: OTHER briefSummary: The goal of this clinical trial is to determine the role of vitamin C on recurrence of gingival pigment after patients who are healthy and esthetically concerned with it received surgical removal of this pigment. The main question\[s\] it aims to answer are:
Researcher will compare the groups who received injectable vitamin C with those who topically applied it to see the effect of each. conditions: Gingival Pigmentation studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: All participants receive surgical depigmentation then either vitamin C is applied following 2 regimens primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Coding of the groups whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Injectable applied vitamin C name: Topical applied Vitamin C name: Surgical depigmentation only measure: Pigmentation scores measure: Assessment of pigment surface area (SA) measure: Assessment of pigment intensity in terms of mean darkness value (MDV) measure: Patient satisfaction measure: Histological response sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Faculty AinShams University status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False